Key takeaways
- The 2nd Annual BGTs Meeting brings together community oncologists, translational researchers, and genomics experts to explore the cutting edge of biomarker-driven oncology.
- Biomarkers are shaping personalized prostate cancer care.
- Predictive biomarkers and serial testing are advancing personalized care in lung cancer.
- Advances in neuro-oncology and CNS metastases are shaping future treatment directions.
Nagla Abdel Karim, Medical Oncologist and Clinical Researcher Specializing in Thoracic Oncology at the George Washington University Cancer Center, shared insights from BGT26 on X:
“An excellent summary of the Biomarker Roadmap for prostate cancer BGT26 Chadi Nabhan, Karima Oualla.
Wandeful talk from Karine Tawagi. What is your daily practice managing patients with prostate cancer?
It was a great pleasure being part of the BGTs for lung cancer panel.
We discussed the critical role of predictive Biomarkers and serial testing along with the new data in NSCLC and SCLC with the feasibility of testing SCLC awaiting potent therapies and biomarkers.
Misty Dawn Shields post WCLC26 and during BGTs in Chicago. Catching up on more data in lung cancer and predictive biomarkers.
Sonikpreet Aulakh BGTs It is always great to meet with you!
Neurononcology, Brain Metastasis, leptomeningeal disease; so much to update the panels about and ask about the future directions!
From the healthcare unfiltered Arabic Podcast to the Book of Toxic Exposures to BGTs Annual Conference!
It has been a pleasure working with my colleague Chadi Nabhan.
Everyday, there is a new subject to explore!
